Vivani Medical Inc VANI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VANI is a good fit for your portfolio.
News
-
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Thinking about buying stock in Ocean Biomedical, Rush Street Interactive, Vivani Medical, Abeona Therapeutics, or Honest Company?
-
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
-
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
-
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
Trading Information
- Previous Close Price
- $1.72
- Day Range
- $1.73–1.79
- 52-Week Range
- $0.84–7.80
- Bid/Ask
- $1.73 / $1.80
- Market Cap
- $97.86 Mil
- Volume/Avg
- 74,262 / 3.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 37
- Website
- https://www.vivani.com
Comparables
Valuation
Metric
|
VANI
|
PNT
|
IMVT
|
---|---|---|---|
Price/Earnings (Normalized) | — | 11.36 | — |
Price/Book Value | 4.38 | 3.12 | 6.16 |
Price/Sales | — | 5.50 | — |
Price/Cash Flow | — | 13.90 | — |
Price/Earnings
VANI
PNT
IMVT
Financial Strength
Metric
|
VANI
|
PNT
|
IMVT
|
---|---|---|---|
Quick Ratio | 3.61 | 9.01 | 21.56 |
Current Ratio | 4.03 | 9.14 | 22.14 |
Interest Coverage | — | — | — |
Quick Ratio
VANI
PNT
IMVT
Profitability
Metric
|
VANI
|
PNT
|
IMVT
|
---|---|---|---|
Return on Assets (Normalized) | −46.51% | 20.67% | −43.33% |
Return on Equity (Normalized) | −73.03% | 23.56% | −47.83% |
Return on Invested Capital (Normalized) | −52.13% | 23.38% | −52.69% |
Return on Assets
VANI
PNT
IMVT
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sjjjdwjkd | Jmfx | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lxblkph | Vffdwwd | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gwjbrsdxh | Fgrjyr | $103.7 Bil | |
MRNA
| Moderna Inc | Cpmmqlgxw | Xshq | $47.9 Bil | |
ARGX
| argenx SE ADR | Vmwvqbvp | Cfmdf | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Zfkmgksm | Mzlgw | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fwbystcc | Mynjzhb | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Frvtnmy | Yrkhrd | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wylwvxgql | Qlljj | $12.8 Bil | |
INCY
| Incyte Corp | Nbbjhqz | Vfxhjw | $12.1 Bil |